Waltham · Pre-Seed–Late Stage · 26 people tracked
Also known as AGENT CAPITAL, LLC
Find your way into Agent Capital
2,349 people in our graph share verified history with the Agent Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Agent Capital is a healthcare-focused venture firm backing novel and differentiated therapeutics aimed at unmet patient needs. It invests across all stages of development and collaborates with scientists, entrepreneurs, and co-investors to advance the next generation of healthcare innovations. The firm takes a balanced investment approach grounded in an understanding of biopharma pipeline pressures, proactively guiding biotech companies toward key milestones and exits. Its typical areas of focus include rare diseases, oncology, neurology, and immunology, and it is willing to invest regardless of stage or investment type.
Source: firm website, verified Sep 15, 2026.
Team · 26 people
from the firm's website & curated
Founder mafia
4 people who came through Agent Capital went on to found or lead other companies.
What they invest in
from 48 of 53 portfolio companiesBiotech ×41Healthtech ×28Medical Devices ×14Deep Tech ×11AI & Machine Learning ×8Digital Health ×8Advanced Manufacturing ×2Enterprise Software ×2
HQs:United States×34United Kingdom×3Japan×1Kenya×1
Who they back
founder profiles across 10 portfolio companiesFounding team size:solo founder×52 founders×33 founders×14+ founders×1
Where their founders studiedfrom 11 founders with education data
Dartmouth College ×2The Johns Hopkins University School of Medicine ×2
What their founders studiedfrom 11 founders with field-of-study data
Life Sciences ×6Physics ×2
Investments · 53 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 52024 · 22023 · 32022 · 32021 · 42020 · 12019 · 42017 · 12015 · 12014 · 128 dated
Pyxis Oncology is a clinical-stage biotech company developing antibody-drug conjugates for solid tumors, with its lead candidate targeting a fibronectin variant found in tumor tissue but not healthy tissue.
HealthtechBoston, US
Thomas Civik(Interim Chief Executive Officer, Director)
BoardDavid Steinberg(Executive Officer, Director)inChristoph Westphal(Director)Jak Knowles(Director)John Flavin(Director)
Board seatGeeta Vemuri· per SEC Form D
Co-investorsLongwood FundRA CapitalRTW Investments L.P.
BiotechWarrington, US
Mary B. Templeton(Executive Officer)Craig E. Fraser(Executive Officer, Director)Lawrence A. Weinstein(Executive Officer)Kathryn Cole(Executive Officer)John Tattory(Executive Officer)George Cox(Executive Officer)in
Board seatBruce Peacock· per SEC Form D · $26.4M raise · filed Dec 2019
Co-investorsPanacea Venture
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Board seatJohn Orloff· per SEC Form D
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersQuan CapitalSR One Capital Management+1 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)
Co-investors5AM VenturesMPM BioImpactMRL Ventures FundRoche Venture FundTCG Crossover
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+9 more
GoDaddy provides domain registration, website building, e-commerce, hosting, and business management tools primarily for small business owners, web designers, and domain investors, bundling domain identity services with marketing and commerce capabilities.
Bob Parsons(Founder)inAman Bhutani(Chief Executive Officer)inMark McCaffrey(Chief Financial Officer)inRoger Chen(Chief Operating Officer)Jared Sine(Chief Strategy and Legal Officer)in
Co-investorsAnsa CapitalCitta CapitalCrimson Investment FundCyverse CapitalFiddlehead VenturesHealthtech Capital+8 more
Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
BiotechDigital HealthHealthtechMedical DevicesWayne, US
Wesley H. Kaupinen(President, Chief Executive Officer and Director)Matthew E. Korenberg(Chief Financial Officer, Treasurer and Secretary)inKathleen Goin(Chief Operating Officer)inJeffrey Martini(Chief Scientific Officer)inAshley Kline(Chief Commercial Officer)in
Co-investorsBioAdvanceFrazier Life SciencesSamsara BioCapital
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.
BiotechSouth San Francisco, US
Bernard Coulie(Executive Officer, Director)inJohannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)inKeith Cummings(Chief Financial Officer)inLily Cheung(Chief Human Resources Officer)inMinnie Kuo(Chief Operating Officer)in
Co-investorsMenlo VenturesThird Rock Ventures
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
Co-investorsage1Aliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+4 more
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures5AM Ventures+2 more
āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers.
BiotechHealthtechBurlingame, US
Pankaj Bhargava(Founder & Chief Executive Officer)inVictoria Smith(Chief Scientific Officer)Deborah Wenkert(Chief Medical Officer)inJoseph Sarret(Acting Chief Operating Officer)Brian Shuster(Acting Chief Business Officer)
Co-investorsMPM BioImpact
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)
Board seatBruce Peacock· per SEC Form D · $5M raise · filed Jan 2020
Co-investorsAvego BioScience CapitalHealthCapBiotechnology Value FundCowen Healthcare InvestmentsJohnson & Johnson Innovation – JJDCNorthpond Ventures
The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.
ConsumerGamingHealthtechBoston, US
Robert Kotin(Executive Officer, Director)Chen Schor(Director)Robert Hadfield(Executive Officer)John Lawrence(Executive Officer)
BoardDerek Yoon(Director)in
Board seatGeeta Vemuri· per SEC Form D
Co-investorsAstellas Venture Management LLCDC Investment PartnersSolasta VenturesUTokyo Innovation Platform Co. Ltd.Longwood Fund
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Board seatBruce Peacock· per SEC Form D
Co-investorsAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHHealthCapMRL Ventures FundSolasta Ventures+3 more
Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions.
BiotechDigital HealthHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Director)Kevin Hanley(Executive Officer)Michael Goldstein(Executive Officer)inDaniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)inDonald Notman(Executive Officer)in
Board seatBruce Peacock· per SEC Form D · $37.5M raise · filed Mar 2019
Co-investorsAscension VenturesSofinnova VenturesSV Health InvestorsTop Corner Capital
BiotechMt. Arlington, US
Paul Chaney(Executive Officer, Director)
BoardAbbie Celniker(Director)inDavid Guyer(Director)Kevin Starr(Director)inLutz Giebel(Director)
Board seatBruce Peacock· per SEC Form D · $47.3M raise · filed Apr 2019
Co-investorsAstellas Venture Management LLCSV Health InvestorsThird Rock Ventures
Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities.
BiotechHealthtechLongevity
Co-investorsOlive Tree CapitalService Provider CapitalFred Hutchinson Cancer Research CenterHumboldtLeaps by BayerVida Ventures
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)HBM Healthcare Investments+2 more
Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease.
BiotechHealthtechPhiladelpia, US
Errik Anderson(Executive Officer, Director)inRoss Leimberg(Executive Officer, Director)in
BoardJoshua Brandt(Director)Geeta Vemuri(Executive Officer, Director)in
Co-investors82VS
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsForesite CapitalGV (Google Ventures)Dementia Discovery FundSV Life SciencesDementia DiscoveryLightstone Ventures+3 more
Cyrus operates a protein engineering platform that combines AI and Rosetta computational design methods with a biochemistry lab performing large-scale deep mutagenesis scanning, protein stabilization, immunogenicity reduction, and affinity/specificity tuning.
AI & Machine LearningBiotechDeep TechSeattle, US
Yifan Song(CSO)inDavid Baker(Co-founder)Javier Castellanos(Executive Officer, Director)inMark(President & EVP, Business Development)
BoardLucas Nivon(CEO)in
Co-investorsAnzu PartnersArgonautic VenturesiSelect FundOrbiMedSPRINGROCK VENTURESStrawberry Creek Ventures+2 more
Dragonfly develops immunotherapy treatments that leverage the body's immune system to treat cancer and autoimmune diseases.
BiotechHealthtechMedical Devices
Tyler Jacks, Ph.D.(Co-founder)Bill Haney(Co-founder, Chief Executive Officer & Chairman of the Board of Directors)David Raulet, Ph.D.(Co-founder)
Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.
Advanced ManufacturingBiotechFoodTechNew Materials
Will Milligan(CEO & Founder)in
Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly Capital5AM VenturesCatalio Capital Management+8 more
Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.
Enterprise SoftwareGovTechSaaSNairobi, KE
Co-investors4Di CapitalInovia CapitalBase10 PartnersWhite Star Capital
Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.
Crypto & Web3Data & Infrastructure
Co-investorsDigital Currency GroupBase10 PartnersInovia CapitalWhite Star Capital
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesCasdin CapitalInvusNextech Invest+2 more
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.
AI & Machine LearningBiotechDeep TechHealthtech
Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in
Co-investorsNexTech VenturesPfizer VenturesThird Rock VenturesNextech InvestPfizer Venture InvestmentsShangBay Capital LLC
Foresight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types.
BiotechDigital HealthHealthtechBoulder, US
Co-investorsBoulder VenturesCivilization Ventures Management, LlcCU Healthcare Innovation FundForesite Capital
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova Partners+1 more
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)Paul Brunetta(Chief Medical Officer)in
Co-investorsPoint72Baruch Future VenturesInVivium CapitalRidgeback Capital
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Daniel Olive(Founder)
Co-investorsAndera PartnersKurma PartnersPfizer Venture InvestmentsPureos BioventuresAlexandriaBpifrance+4 more
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsDC Investment PartnersLongwood FundMedical Excellence CapitalNovartis Venture FundOno Venture Investment, Inc.Solasta Ventures+3 more
Ivee provides AI training, strategy, and policy development services for organizational teams, including custom training programs, AI audits, policy writing, and tool integration guidance.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareFuture of WorkHR TechLondon, GB
Lydia Miller(Founder)inAmelia Miller(Founder)in
Co-investorsTechstarsFJ LabsGaingelshumbitionLooking Glass CapitalTribe Capital
__Twitter.png)
Jana Care offers a smartphone-enabled at-home blood testing system using its Aina device, paper test strips, and a mobile app to detect key biomarkers for chronic disease management.
Digital HealthHealthtechMedical DevicesWatertown, US
Sidhant Jena(Executive Officer, Director)Timothy Richards(Executive Officer)Richard Williams(Executive Officer)inAnh Hoang-Lindsay(Executive Officer, Director)Michal Depa(Executive Officer, Director)
BoardEhsan Jabbarzadeh(Director)
Co-investorsHealthXCapitalPatamar CapitalFirst Avenue VenturesIAG Capital PartnersThe A-Team
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLC+3 more
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.
BiotechDeep TechMedical DevicesBerkeley, US
Brian Thomas(Executive Officer, Director, Promoter)in
BoardAndrew Farquharson(Director)inJak Knowles(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesFrazier Life SciencesHumboldtInCube Ventures+5 more
Nu-Tek BioSciences manufactures plant- and yeast-based cell culture nutrients and fermentation supplements for pharmaceutical and biotechnology companies.
Advanced ManufacturingBiotechImpact & Social GoodNew MaterialsMinnetonka, US
Thomas Yezzi(Founder & CEO)Kent McCoy(Chief Financial Officer of the Issuer)in
Co-investors1315 Capital
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersNewpath PartnersREDMILE
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.
BiotechHealthtechAptos, US
Jason Levin(Founder, Director and Chief Executive Officer)Robert M. Myers(Executive Officer, Director)
BoardMichael Wasserman(Director)Patrick Enright(Director)inElisha (Terry) Gould(Director)Ernest Mario(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalAbingworthAdams Street Partners
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology FundBaillie GiffordORI Capital+1 more
Primrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms.
BiotechDeep TechMedical DevicesSan Diego, US
Helge Zieler(Director, Executive Officer)inDrew Burch(Chief Executive Officer)Diane Retallack, PhD(President & Chief Operating Officer)
BoardJ. Todd Mitchell(Director)Matthew Korenberg(Director)Matthew Reber(Director)
Co-investors1315 Capital
Skyhawk Therapeutics develops RNA-targeting small molecule drugs using its SKYSTAR platform to modify RNA expression, addressing diseases in neurology, oncology, and fibrotic conditions.
BiotechDeep TechWaltham, US
Kathleen McCarthy(Founder)
Co-investorsDns CapitalGood Growth CapitalGreatPoint VenturesShangBay Capital LLC
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesBlue Owl Capital+9 more
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsAvego BioScience CapitalDelos CapitalPfizer Venture Investments
Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Francisco, US
Alice Zhang(Co-founder & CEO)inJason Chen(Cofounder)inEmily Ripka(Head of Product & Engineering)in
Co-investorsBOLD LongevityDraper AssociatesFitz Gate VenturesGreat Oaks Venture CapitalKarlin VenturesLifeforce Capital+5 more
Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsLongwood FundPfizer Venture Investments
Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types.
BiotechDeep TechMedical DevicesPhiladelphia, US
Nicholas Siciliano(Director)inPreston Noon(Executive Officer)
BoardGeeta Vemuri(Executive Officer, Director)Bruce Peacock(Executive Officer, Director)Leon Moulder(Director)
Co-investorsBioAdvanceGlobal BioAccess Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BenevolentAIDicemoleculesInterius BioTherapeuticsPalvella Therapeuticsvisit www.interiusbio.com
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 13
10 IPOs · 3 acquisitions · showing 12Pyxis OncologyNASDAQ: PYXSWindtree Therapeutics INC /DeOTC: WINTZenas BiopharmaNASDAQ: ZBIOEntrada Therapeutics, Inc.NASDAQ: TRDAFreenomeNASDAQ: FRNMGoDaddyNYSE: GDDYPalvellatxNASDAQ: PVLAPliant TherapeuticsNASDAQ: PLRXPrecision BioSciencesNASDAQ: DTILQ32 BioNASDAQ: QTTBForesight Diagnosticsacq. by NateraImcheckacq. by Clementia
Portfolio news
latest coverage across their companies
Pyxis Oncology · scanx.trade · Aug 20, 2026
Alveus Therapeutics · fiercebiotech.com · Aug 12, 2026
Metagenomi · za.investing.com · Aug 11, 2026
Orchard Therapeutics · x.com · Aug 8, 2026
Precision BioSciences · tradingkey.com · Aug 6, 2026
Q32 Bio · stocktitan.net · Aug 5, 2026
Flare · coindesk.com · Jul 30, 2026
Flare · allsci.com · Jul 1, 2026
Frequently asked questions
- How many investments has Agent Capital made?
- Agent Capital has 53 tracked investments, 13 of which have exited, including 9 dated in the last 24 months.
- What stage does Agent Capital invest at?
- Agent Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Agent Capital focus on?
- Agent Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Agent Capital located?
- Agent Capital is headquartered in Waltham, US.
- Does Agent Capital lead rounds?
- Yes, Agent Capital leads investment rounds.
- Who does Agent Capital co-invest with?
- Agent Capital most often shares deals with Longwood Fund, OUP (Osage University Partners), Pfizer Venture Investments, among 82 tracked co-investors.
- What size deals does Agent Capital back?
- Across 6 deals with disclosed amounts, Agent Capital has joined rounds of $3M – $76M (median $17M).
Images
Co-investors · 12
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Trinity Ventures is an early-stage venture capital firm that invests in mission-driven entrepreneurs and their companies.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
AbbVie Ventures is the corporate venture capital arm of biopharmaceutical company AbbVie, investing in early-stage companies in oncology, immunology, and neurodegenerative diseases that complement the parent company's research and development pipeline.
Cofounders Capital is a North Carolina-based venture firm that leads seed-stage investments in B2B software companies across the southeastern United States.
Firms observed investing alongside Agent Capital, from public investor directories. Shared companies are the overlap with Agent Capital's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.